[Safety of radioiodine therapy in patients with thyroid carcinoma younger than 21 years].
We studied 20 patients with differentiated thyroid carcinoma undergoing radioiodine therapy (> or = 100 mCi dose) before the age of 21: 10 patients without distant metastases received a mean dose of 145 mCi and 10 with lung involvement received 270 mCi. One or more years after ablative therapy, xerostomia was present in two patients but was not accompanied by more severe complications such as oral ulcers or fissures, and 99mTcO4- scintigraphy confirmed salivary dysfunction. One patient showed keratoconjunctivitis sicca. Blood counts did not reveal abnormalities caused by radioiodine therapy. FSH was normal in 18 patients. Patients with elevated levels had received radioiodine just over a year ago and repetition of the exam after 6 months showed that FSH had returned to normal. The 6 male patients had normal LH and testosterone levels. Analysis did not reveal signs of pulmonary fibrosis secondary to treatment in the 10 cases with iodine-accumulating metastases in this organ. Our data suggest that ablative therapy employing a dose of 100 to 300 mCi is safe in young individuals, but persistent complications such as salivary dysfunction and conjunctivitis may occur.
Rosário
Pedro Weslley S
PW
Departamento de Tireóide, Clínica de Endocrinologia e Metabologia, Serviço de Medicina Nuclear, Santa Casa de Belo Horizonte, MG. pedrorosario@globo.com
Cardoso
Ludmilla David
LD
Barroso
Alvaro Luís
AL
Padrão
Eduardo L
EL
Rezende
Leonardo Lamego
LL
Purisch
Saulo
S
D000293:Adolescent; D000328:Adult; D002277:Carcinoma / Q000532:radiotherapy*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D016896:Treatment Outcome
D007457:Iodine Radioisotopes